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Evaluation of a PACAP peptide analogue labeled with 68Ga using two different chelating
agents.
Pardeep Kumar1, Sushil Tripathi1, Chang-Po Chen2, Neil Mehta1, Bishnuhari paudyal1, Eric
Wickstrom3,4, Mathew L. Thakur*1,4,5.
ABSTRACT
Objective: The authors have conjugated chelating agents (DOTA and NODAGA) with a peptide
(PACAP analogue) which has a high affinity for VPAC1 receptors expressed on cancer cells. In
order to determine a suitable chelating agent for labeling with 68Ga, we have compared the
labeling kinetics and stability of these peptide conjugates.
Methods: For labeling, 68GaCl3 was eluted in 0.1 M HCl from a [68Ge-68Ga] generator. The
influences of peptide concentration, pH and temperature on the radiolabeling efficiency were
studied. The stability was evaluated in saline, human serum, DTPA, Transferrin and metallic
ions (FeCl3, CaCl2 and ZnCl2). Cell binding assay was performed using human breast cancer
cells (T47D). Tissue biodistribution was studied in normal athymic nude mice.
Results: Optimal radiolabeling (> 95.0%) of the DOTA-peptide conjugates required higher
(50°C–90ºC) temperature and 10 min incubation at pH 2–5. The NODAGA-peptide conjugate
needed incubation only at 25°C for 10 min. Both radio-complexes were stable in saline, serum as
well as against transchelation and transmetallation. Cell binding at 37°C for 15 min incubation
with 68Ga-NODAGA-peptide was 34.0% as compared to 24.5% for 68Ga-DOTA-peptide. Tissue
biodistribution at 1 hr post-injection of both 68Ga labeled peptide conjugates showed clearance
through the kidneys.
Conclusions: NODAGA-peptide showed more convenient radiolabeling features than that of
DOTA-peptide.
Key words: Breast cancer, Prostate Cancer, chelating agent, peptides, radiopharmaceuticals.
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Introduction
Positron emission tomography (PET) has become a prominent imaging modality in the field of
oncology.1 PET has several technical advantages over the single photon emission computed
tomography (SPECT) like attenuation correction, and higher spatial resolution.2-3 Small
molecules such as sugars, amino acids, nucleic acids, or receptor-binding ligands are labeled
with positron-emitting radionuclides for PET imaging to study in vivo visualization of
physiological processes on a molecular level.4-7 There are several positron emitting radionuclides
like fluorine-18 [18F] (t1/2 ≈ 110 min), copper-64 [64Cu] (t1/2 ≈12.7 hr), carbon-11 [11C] (t1/2 ≈ 20
min), and oxygen-15 [15O] (t1/2 ≈ 2 min). However, their production requires in-house cyclotron,
not available at every academic institution and hospital.
In recent years, Gallium-68 [68Ga] - a positron emitting radionuclide conveniently available in
the form of Germanium-68 (t1/2 ≈ 270 days)-Gallium-68 (t1/2 ≈ 68 min) [68Ge 68Ga] generator
has drawn considerable attention for oncologic diagnostic applications. The short physical halflife of 68Ga induces low radiation burden on patients and makes it an ideal radionuclide for
diagnostic use.8-10 The labeling of biomolecules with 68Ga is achieved by using bi-functional
chelators (BFC) such as DTPA (diethylene triamine pentaacetic acid), DOTA (1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid), NOTA (1,4,7-triazacyclononane-1,4,7-triacetic
acid), or NODAGA (1,4,7-triazacyclononane-1-glutamic acid-4,7-diacetic acid). BFCs differ
from each other in their physio-chemical properties which can influence radiolabeling kinetics.
They can also influence overall charge of the complex, biodistribution and more importantly
uptake in the tumor site.11-13
In recent years, there has been increasing interest in the receptor targeted scintigraphy in which
peptides have emerged as promising biomolecules.14 Their properties such as fast clearance,
rapid tissue penetration, low antigenicity, and relatively easy synthesis have added to their
applicability.15 In past few years, our laboratory has designed, synthesized and radiolabeled
peptide conjugates which have high affinity for VPAC-1 receptors, over-expressed in many
malignant tumors including those of the breast and prostate.16-20 The peptides are analogues of
Pituitary adenylate cyclase-activating peptide (PACAP) - a 27 amino acid peptide and vasoactive
intestinal peptide (VIP)- 28 amino acid. Both have similar biochemical properties and bind to
VPAC1 receptors expressed in high density on the surface of certain cancers such as of the
breast, prostate and urinary bladder (100%), colon (96%), pancreas (65%), lung (58%), stomach
(54%), and liver (49%).21-24
The present study was aimed to investigate the influence of these two BFC agents on the PACAP
analogue, which differs in terms of their radiolabeling kinetics, biological activity and stability of
the resultant product.

Methods and materials
Reagents
Fmoc amino acid, solvents and reagents for peptide chelator synthesis, was purchased
from Fluka Chemicals (St. Louis, MO). The BFC DOTA was purchased from
Macrocyclics (Dallas, TX) and NODAGA was purchased from Chematech (Dijon,
France). Sodium acetate, diethylenetriamine pentaacetic acid (DTPA), calcium chloride
(CaCl2), zinc chloride (ZnCl2), Ferric chloride (FeCl3), hydrochloric acid solutions were
purchased from Fisher Scientific, Inc. (Waltham, MA). Transferrin was purchased from
Sigma-Aldrich (St. Louis, MO). A 370MBq [68Ge-68Ga] generator was purchased from
Eckert and Zeigler (Berlin, Germany). Sodium chloride solution (0.9%) was prepared in
this laboratory using deionized water. Human serum was prepared from whole blood
drawn from a volunteer. All chemicals were used without further purification.
Instruments
Peptide was purified using a preparative column on high-pressure liquid chromatography
(HPLC) system (Shimadzu Corporation, Kyoto, Japan) equipped with gradient pumps
and UV/VIS detector, a NaI(Tl) radioactivity monitor, and a rate meter. The reverse
phase C18 microbound column (4.6 mm × 250 mm) served as the stationary phase, and
two solvents: 0.1% Trifluoroacetic acid (TFA) in H2O and 0.1% TFA in acetonitrile as
mobile phase. The gradient was such that 10% CH3CN in aqueous 0.1% CF3COOH to
100% CH3CN in 0.1% CF3COOH at a flow rate of 1 mL/min over 28 min at 22°C. For
thin layer chromatography (TLC), pre-coated aluminum sheets with silica gel were
purchased from Merck (Kenilworth, NJ) and radioactivity was measured on Perkin Elmer
2480 wizard2 automatic gamma counter (Waltham, MA). The pH of the solutions was
measured using either a pH meter (Sartorius, Gottingen, Germany) or pH strips (Fisher
scientific Inc.)
Synthesis of peptide conjugate
Briefly, the PACAP analogue with C-terminal NODAGA/DOTA chelators was
synthesized on a Wang resin using an ABI 341A peptide synthesizer (Applied
Biosystems, Foster City, CA). Fmoc-Lys (ivDde) was first introduced at the C terminus
of the peptide, followed by 4-aminobutyric acid (y-Aba). The 27-amino-acid-long
PACAP sequence was then assembled by standard Fmoc coupling with the final histidyl
residue, being a t-Boc–protected His(Trt) derivative. The capping t-Boc function was
necessary to ensure that the N-terminal amino group remained protected during

subsequent deprotection and coupling cycles performed at the c amino group of the Cterminal lysine. The ivDde group at the C-terminal lysine was then selectively removed
with 2% hydrazine, followed by coupling with DOTA or NODAGA. The peptide was
cleaved from the resin using TFA/water/ phenol/thioanisole/ethanedithiol (82.5:5:5:5:2.5)
and precipitated with diethyl ether. The crude peptide was purified to homogeneity by
reversed phase HPLC using a preparative column. The peptide was characterized by
matrix-assisted laser desorption/ionization- time of flight (MALDI-TOF) mass
spectrometry.
Radiolabeling
For radiolabeling, 300 µL (14.5 – 18.5 MBq) of 68GaCl3 was added in a clean glass test
tube to which were added varying amounts of acetate buffer to study the influence of pH
(1.0 – 6.0) and varying amount of a 4 mg/mL peptide-chelators water solution (1-20 µg).
The mixture was heated at predetermined temperatures (25, 50, 70 and 90 °C) for pre
chosen time periods (10, 15, 20 and 30 min) to study the kinetics of the radiolabeling
reactions with respect to temperature and time. The radiolabeling was evaluated by
Radio-HPLC.
Preparation of free
standard
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GaCl3,

68

Ga-hydrolyzed,

68

Ga-DTPA and

68
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To identify HPLC peaks of the 68Ga species, HPLC peaks, that may have formed during
the chelation experiments, free 68GaCl3 (as eluted from generator with 0.1M HCl), 68Gahydrolyzed products, 68Ga-DTPA and 68Ga-Transferrin (Tf) were prepared as described2526,13
and their retention times were recorded on radio-HPLC.
Stability (in vitro), transchelation and transmetallation studies
For the stability, transchelation and transmetallation studies, 68Ga-peptide-chelators were
prepared by mixing 300 µL (14.5 – 18.5 MBq) of 68GaCl3 in 0.1 M HCl, 120 µL of 1.0 M
sodium acetate and 5 µL (20 µg) of peptide-chelators. The preparation was incubated at
90°C for 30 min. Aliquots of 68Ga-peptide-chelators solutions (0.3 mL, approx. 15 MBq)
were alternatively mixed with (1) 0.3 mL of a 0.9% NaCl, (2) 0.3 mL of a 100 nM
Fe3+/Zn2+/Ca2+(for transmetallation study), (3) 0.3 mL of a 200 μM DTPA solution, (4)
0.3 mL of a 50 μM transferrin solution (for transchelation study) and (5) 0.3 mL of
human serum solution. The mixtures were incubated at 37 °C and analyzed after 0, 10,
30, 60 and 120 min of incubation, respectively. A 10 μl (in 100µL of normal saline)
aliquot preparations of (1), (2) and (3) were injected in the radio-HPLC while
preparations (4, 5) were analyzed by ITLC-SG using 0.1M citric acid as a solvent.

Cell binding (in vitro) assay
Estrogen receptor-positive T47D human breast tumor cells from American Type Culture
Collection were maintained in RPMI 1640 medium with 2 mM L-glutamine contained 10
mM HEPES, 1.0 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and
supplemented with 0.2 Units/ml 90 %bovine insulin, and 10% fetal bovine serum, at
37°C under 5% CO2/95% air. The cells when confluent were detached using 0.25%
trypsin-EDTA, washed and resuspended with RPMI-1640 medium at a concentration of ~
5× 106 cells/mL. Each test tube contained 1 mL of cell suspension into which 10 µL of
68
Ga-peptide-chelator (approx. 0.74 MBq) was added and incubated for 2 hr at 37°C in a
water bath. The incubation was terminated by adding 0.5 ml of cold normal saline. The
mixture was centrifuged at 3000 rpm for 10 minutes. The supernatant from each wash
was collected into marked test tubes. To the remaining pellet, 1.0 ml of normal saline was
added and centrifuged again at 3000 rpm for 10 minutes. The supernatant was separated
and collected in the marked test tube. The cells and supernatant were counted for
radioactivity in a gamma counter and percentage of radioactivity bound on the cells was
calculated.
Biodistribution studies
The biodistribution of 68Ga labeled peptide was studied in normal (n = 10, athymic nude,
female mice, 20-25 g). The resultant optimal preparation procedure was used which
contained 300 µL of 68GaCl3 in 0.1 N HCl, 120 µL of 1.0 M sodium acetate solution
and 20 µg of peptide conjugate, incubated for 10 min at RT (for NODAGA-peptide) and
90ºC (for DOTA-peptide). Following determination of radiochemical purity (> 95%) by
radio-HPLC analysis, 68Ga-peptide (3.7 – 5.5 MBq) was administered intravenously
through a lateral tail vein in 200 µL of the preparation (pH ≈ 5.5). Radioactivity in the
syringe before and after administration was measured in an energy-calibrated dose
calibrator (CRC-15; Capintec, Ramssey, NJ), and the exact quantity received by each
animal was determined. A standard 68GaCl3 solution of a known quantity was prepared at
the time of injection. The animals (n = 5, each study) were sacrificed at 1 h post injection
by CO2 inhalation. Various organs were removed, washed free of blood, blotted dry, and
weighed. The associated radioactivity was counted in the γ-counter and results were
calculated as percentage injected dose per gram (% ID/g) of tissue.

Results
Purity of peptide-chelators conjugates
NODAGA- and DOTA-peptide purity as determined by HPLC was 99%. The MALDITOF demonstrated that, for NODAGA-peptide observed molecular mass was 3716
(calculated molecular mass-3718) whereas for DOTA-peptide observed molecular weight
was 3787 (calculated molecular mass-3785). The MALDI peaks for the peptide
conjugates are given in Figure 1A and B.

Radiolabeling kinetics
Optimal radiolabeling (> 95.0%) of the DOTA-conjugated peptide required pH 2-5 and
higher (50-90ºC) temperature, while the NODAGA conjugated peptide needed incubation
only at room temperature at same pH range. At higher temperature (90°C), the
radiolabeling was not affected by pH for both peptide conjugates (Fig. 2A, B) and can be
labeled at wide range of pH (1.0 – 6.0). NODAGA-peptide can bind 68Ga at a minimal
quantity of 1 µg but DOTA-peptide required minimum of 20 µg to yield optimal (≥ 95%)
radiolabeling (Fig. 2C). The minimum incubation time needed for optimal (> 95%)
radiolabeling was 10 minutes at 90°C (Fig. 2D). Radio-HPLC showed retention time for
both radio-complexes was 9.9 ± 0.3 minutes as compared to 3.1 ± 0.2 minutes for free
68
Ga as shown in Fig. 3-b. The retention time was also determined for the reference
standard like hydrolyzed 68GaCl3, 68Ga-DTPA and 68Ga-transferrin and found to be 3.5 ±
0.2 minutes.
Stability studies
Both 68Ga labeled peptide conjugates were stable in 0.9% normal saline (Fig. 4A) and
showed minimal (1-2%) degradation against (FeCl3, CaCl2 and ZnCl2) transmetallation
(Fig. 4B-D) up to 2 hours. The transchelation study with DTPA (Fig. 5A) and transferrin
(Fig. 5B) solution showed that both radio-complexes were remained intact over 2 hours.
Radio-TLC showed ratio factor (Rf) value of 0.0-0.1 for 68Ga labeled peptide and 0.9-1.0
for free 68GaCl3..

Cell binding (in vitro) assay
Cell binding assay showed higher uptake for 68Ga-NODAGA-peptide, 34.0% ± 0.8% as
compared with 24.5% ± 0.9% for 68Ga-DOTA-peptide at 15 minutes. However, at 2

hours of incubation at 37ºC, the uptake was nearly same, 48.9% ± 3.9% for
NODAGA-peptide and 45.2% ± 2.1% for 68Ga-DOTA-peptide (Table – I).

68

Ga-

Biodistribution studies
The biodistribution pattern of the both68Ga labeled peptide conjugate is shown in Figure
6. In both cases, a higher uptake is seen in kidneys followed by liver, blood and lungs. It
was evident that the 68Ga-NODAGA-Peptide showed rapid blood clearance as compared
to 68Ga-DOTA-peptide. Liver uptake was 8.8% for 68Ga-NODAGA-Peptide was lower (p
= 0.01) as compared to 16.5% for 68Ga-DOTA-peptide. Most of the activity was excreted
through kidney.
Discussion
With its several advantages such as the availability in a generator form, cyclotron
independency, multi elution ability in a single day, simplified radiolabeling chemistry
with several biomolecules using bifunctional chelating agents, the use of 68GaCl3 is
rapidly growing for diversified clinical applications.27 The presence of even µg levels of
metallic impurities (with ageing of generator) in 68GaCl3 or reagent used may hamper the
radiolabeling complexation. The removal of radionuclide impurities however has helped
expansion of its use for clinical application.28
The eluate of 68GaCl3 from the generator may contain metal ion impurities such as Fe3+,
Cu2+, Al3+, Zn2+ and Sn4+ which could hamper the radiolabeling of biomolecules. It is
important therefore to identify the suitable chelating agent for the radiolabeling which is
least affected by these impurities as well the stability of the labeled compound.29-30
DOTA is the most commonly used chelating agent and 68Ga-DOTATOC is accepted in
the European Pharmacopeia.31 68Ga labeled DOTA biomolecules conjugates (like
peptides, antibody, and small molecules) have been successfully developed and used for
many clinical applications. The disadvantage of DOTA conjugate is its slow reaction
kinetics for complex formation with 68Ga.32 These limitations prompted us to investigate
the use of NODAGA for comparison with DOTA.
Chelator-peptide conjugates were synthesized by solid phase peptide synthesis method.
Both peptide conjugates were synthesized with high purity (~ 99.0%). NODAGApeptide conjugate showed faster kinetics as compare to DOTA- peptide conjugate and
less influenced by the pH variation. NODAGA peptide conjugate yielded higher
radiolabeling efficiency at minimal quantity of peptide (1 µg), at room temperature and
within short incubation (5 min) time. For the preparations with short lived radionuclides
like 68Ga, these characteristics of NODAGA are advantageous. The faster radiolabeling

kinetics may be attributable to its ionic size compatibility with cavity size of the nine
membered triazomacrocycle of NODAGA and therefore, yielding a high radiolabeling in
5 min at room temperature.33 A low radiolabeling was observed in acidic (pH-1.0)
conditions for both peptide conjugates when incubated at temperature (25-70°C). It may
attribute to strongly acidic environment which might have protonated the donor atoms of
the ligand and destabilized the 68Ga complex.34 At high temperature (~ 90°C), the
radiolabeling was found to be independent of pH variation (Fig. 2 a-b). However at pH 7.0
and above, labeling decreases (data not included). This may be due to a fact that at acidic pH,
68
Ga remains predominant in cation Ga3+ form (> 90%), though soluble complex ions Ga(OH)2+,
Ga(OH)+2 may be present in the solution. As the pH of the solution shifts towards basic (> 7.0),
the hydrolyzed form of Gallium, Ga(OH)-4 increases and decreases the radiolabeling yield.35 Once
the peptide conjugate is radiolabeled, then adjusting the pH to physiological pH 7.0 does not
adversely influence the chelated Ga-68.

The use of sodium acetate buffer maintained the pH and allowed strong formation BFC68
Ga complex. The other advantage of using sodium acetate buffer is its biocompatibility
for human use.36 DOTA peptide conjugate showed labeling at high temperature.
Therefore, DOTA may not be useful for those peptides which can denature at higher
temperature and become unsuitable for molecular imaging. On the other hand,
radiolabeling of NODAGA-peptide at room temperature ruled out major thermal
denaturation. Radio-HPLC showed that the formation of the 68Ga-NODAGA and DOTA
peptide conjugate has retention time of around 9.9 min whereas free 68Ga eluted at 3.6
min (Fig. 3-b) and complex formation between 68Ga and NODAGA-peptide conjugate is
shown in Fig. 3-a . HPLC UV detector also detected the UV peak for NODAGA and
DOTA peptide conjugate at around 9.9 min. Therefore, it confirmed the complexation of
the 68Ga with peptide conjugate which leads to the retention of the 68Ga labeled peptide
approximately at the same time.
Both radio-complexes were found to be stable in normal saline (Fig. 4a) and human
serum over 120 minute. The stability in human serum (at 37°C) indicated its suitability
for in vivo applications and showed their inertness towards the metal ion/species that may
be present in the serum. The transmetallation study was important not because these ions
are present as impurities in the eluate but these ions are also present in serum in
appreciable quantity.37 68Ga-NODAGA and DOTA peptide conjugates showed minimal
(1-2%) degradation in radiolabeling after 120 minute incubation with respective ion
solution at 37°C (Fig. 4-b-d). This could also provide an indication about the stability of
these radio-complexes in in vivo environment. Transferrin is the major protein in the
plasma which is known to form a strong complex with 67Ga-citrate.38 The minimal
transchelation (~1-2%) of 68Ga-peptide conjugates with transferrin showed the stability of
radio-complexation (Fig. 5-a-b).

The cell binding assay was performed on T47D breast cancer lines which express VPAC1 receptors on their surface.19 68Ga-NODAGA-peptide showed higher uptake in 15
minute as compared to 68Ga-DOTA-peptide but the uptake was almost same at 2hr
(Table-1) which may be due to saturation of the receptor site. The biodistribution data
(Fig. 6) showed that both radio-complexes were cleared through kidneys. Hence, renal
system was the major route of clearance from the body. 68Ga-NODAGA-peptide was
cleared rapidly form the blood and had significantly less liver uptake (p < 0.05) as
compare to 68Ga-DOTA-peptide at 1 hr. The fast clearance from the blood may be
advantageous in reducing the background radioactivity for PET imaging but it could also
limit the accumulation of radioactivity at target (tumor) area. Hence, a detailed in vivo
investigation will be required further for any conclusion.
In the present study, we have showed that 68Ga-NODAGA-peptide exhibited most
favorable features from radiochemistry point of view. Chelator NODAGA has flexibility
over the influence of temperature and acidic environment.13 Labeling at room temperature
provides an advantage and could prevent any deleterious effect on peptide conjugate due
to heating. Both peptide conjugates were found to be stable in serum, against
transchelation and transmetallation experimentations. A detailed in vivo study is in
progress to investigate the influence of chelators on the biodistribution and tumor
targeting.
Conclusions
A comparison between NODAGA and DOTA revealed that NODAGA-peptide conjugate
could be efficiently radiolabeled with 68Ga at room temperature with high yield. 68GaNODAGA-peptide conjugate remained stable in serum, in presence of major metal ions
impurities, against transchelation with DTPA or transferrin. The biodistribution data
showed its clearance from kidneys, which minimize the radiation burden on the organs.
The clearance of 68Ga-NODAGA-peptide from blood was faster as compare to 68GaDOTA-peptide and would be advantageous for PET imaging.
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